Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ENSC

Ensysce Biosciences Inc

Jan 02 • 04:00PM ET

8.25

Dollar change +0.11
Percentage change 1.35	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM RARE BCRX OCUL KNSA CRBP EPIX DRRX MNOV XFOR

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-27.26	Insider Own	1.53%	Shs Outstand	1.30M	Perf Week	-17.33%
Market Cap	10.76M	Forward P/E	-	EPS next Y	-12.75	Insider Trans	0.00%	Shs Float	1.28M	Perf Month	-6.78%
Income	-7.93M	PEG	-	EPS next Q	-2.70	Inst Own	26.55%	Short Float	3.56%	Perf Quarter	134.74%
Sales	4.42M	P/S	2.44	EPS this Y	82.30%	Inst Trans	-	Short Ratio	0.02	Perf Half Y	22.22%
Book/sh	7.47	P/B	1.10	EPS next Y	-2.41%	ROA	-125.77%	Short Interest	0.05M	Perf Year	-50.45%
Cash/sh	3.18	P/C	2.59	EPS next 5Y	-	ROE	-188.86%	52W Range	2.12 - 30.90	Perf YTD	1.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-114.75%	52W High	-73.30%	Beta	0.55
Dividend TTM	-	Quick Ratio	3.24	Sales past 5Y	-10.06%	Gross Margin	-	52W Low	289.52%	ATR (14)	1.26
Dividend Ex-Date	-	Current Ratio	3.24	EPS Y/Y TTM	91.81%	Oper. Margin	-142.70%	RSI (14)	52.08	Volatility	10.10% 16.73%
Employees	9	Debt/Eq	0.05	Sales Y/Y TTM	40.41%	Profit Margin	-179.29%	Recom	1.00	Target Price	129.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	107.68%	Payout	-	Rel Volume	0.02	Prev Close	8.14
Sales Surprise	0.59%	EPS Surprise	0.00%	Sales Q/Q	685.26%	Earnings	Nov 14 AMC	Avg Volume	1.82M	Price	8.25
SMA20	8.56%	SMA50	1.82%	SMA200	9.41%	Trades		Volume	33,947	Change	1.35%

Dec-23-24 08:00AM	Ensysce Biosciences Regains Full Compliance with Nasdaq (ACCESSWIRE)
Dec-10-24 08:00AM	Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product (ACCESSWIRE)
Dec-04-24 08:00AM	Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR (ACCESSWIRE) -8.04%
Dec-03-24 04:15PM	Ensysce Biosciences Announces 1-for-15 Reverse Stock Split (ACCESSWIRE) -6.78%
Nov-26-24 08:00AM	Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial (ACCESSWIRE) +14.45%
04:15PM	Loading…
Nov-12-24 04:15PM	Ensysce Biosciences Reports Third Quarter 2024 Financial Results (ACCESSWIRE) +5.10%
Nov-07-24 08:00AM	Ensysce Biosciences Receives Positive Nasdaq Listing Determination (ACCESSWIRE) +26.42%
Oct-08-24 08:00AM	Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit (ACCESSWIRE) -14.87%
Oct-02-24 08:00AM	Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries (ACCESSWIRE)
Sep-27-24 04:30PM	Ensysce Biosciences Receives Notice from Nasdaq (ACCESSWIRE) +5.53% -16.67%
Sep-24-24 08:00AM	Ensysce Biosciences Presenting at Upcoming Meetings (ACCESSWIRE)
Sep-19-24 07:00AM	Ensysce Biosciences Submits Phase 3 Protocol to the FDA (ACCESSWIRE)
Sep-13-24 08:00AM	Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 (ACCESSWIRE)
Aug-29-24 08:00AM	Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants (ACCESSWIRE) -34.67%
08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire)
02:30PM	Loading…
Aug-27-24 02:30PM	Ensysce Biosciences Announces IRB Approval for Key MPAR Study (ACCESSWIRE) +47.06%
08:00AM	Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection (ACCESSWIRE)
Aug-23-24 08:00AM	Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) (GlobeNewswire) +7.54%
Aug-14-24 04:15PM	Ensysce Biosciences Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Aug-08-24 08:25AM	Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium (ACCESSWIRE)
Jul-23-24 08:00AM	Ensysce Biosciences Provides Mid-Year 2024 Update (ACCESSWIRE)
Jul-09-24 08:00AM	Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset (ACCESSWIRE) +5.61%
Jun-27-24 08:00AM	Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting (ACCESSWIRE)
Jun-25-24 08:00AM	Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate (ACCESSWIRE)
Jun-24-24 10:52AM	ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jun-06-24 08:00AM	Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program (ACCESSWIRE)
Jun-03-24 08:00AM	Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting (ACCESSWIRE)
May-28-24 08:00AM	Ensysce Biosciences Regains Compliance with Nasdaq (ACCESSWIRE)
May-20-24 08:00AM	Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform (ACCESSWIRE) +18.43%
May-13-24 08:00AM	Ensysce Biosciences Reports First Quarter 2024 Financial Results (ACCESSWIRE) +11.64%
08:00AM	Loading…
Apr-25-24 08:00AM	Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine (ACCESSWIRE)
Apr-19-24 08:00AM	Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published (ACCESSWIRE)
Apr-09-24 08:00AM	Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (ACCESSWIRE)
Mar-18-24 10:53AM	ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Mar-15-24 08:00AM	Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results (ACCESSWIRE) +5.81%
Feb-27-24 08:00AM	Ensysce Biosciences Receives Positive Nasdaq Listing Determination (ACCESSWIRE)
Feb-21-24 08:00AM	Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection (ACCESSWIRE)
Feb-15-24 08:00AM	Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript (ACCESSWIRE)
Feb-13-24 08:00AM	Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds (ACCESSWIRE) -24.56%
Feb-06-24 08:00AM	Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference (ACCESSWIRE) -6.00%
Jan-31-24 08:00AM	Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain (ACCESSWIRE) +12.50%
Jan-25-24 08:00AM	Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting (ACCESSWIRE) +12.78%
Jan-23-24 08:00AM	Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR (ACCESSWIRE) +21.93%
Jan-08-24 08:15AM	Ensysce Biosciences Issues 2024 Shareholder Letter (ACCESSWIRE)
Dec-19-23 04:15PM	Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023 (ACCESSWIRE) -7.50%
Dec-14-23 08:15AM	Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic (ACCESSWIRE) -5.50%
Dec-11-23 09:00AM	Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast (ACCESSWIRE)
Nov-29-23 08:05AM	Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing (ACCESSWIRE)
Nov-28-23 08:15AM	Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States (ACCESSWIRE)
Nov-16-23 08:15AM	Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study (ACCESSWIRE) +6.56%
Nov-09-23 04:30PM	Ensysce Biosciences Reports Third Quarter 2023 Financial Results (ACCESSWIRE) -6.58% -5.89%
Oct-24-23 08:15AM	Ensysce Biosciences Secures $1.7 Million Convertible Note Financing (ACCESSWIRE) -7.09%
Oct-18-23 08:15AM	Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360 (ACCESSWIRE) +6.48%
Oct-13-23 08:15AM	Ensysce Biosciences Releases 'Highlights Video' of PAINWeek 2023 Symposium (ACCESSWIRE) +7.46%
Oct-11-23 08:15AM	Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit (ACCESSWIRE)
Oct-03-23 08:15AM	Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023 (ACCESSWIRE) -5.26%
Sep-26-23 08:15AM	Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study (ACCESSWIRE)
Sep-19-23 08:15AM	Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023 (ACCESSWIRE)
Sep-14-23 08:15AM	Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies (ACCESSWIRE)
Sep-07-23 08:15AM	Ensysce Presents "A New Generation of Safer Pain Treatments" (ACCESSWIRE)
Sep-05-23 08:15AM	Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-14-23 08:15AM	Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium (ACCESSWIRE)
Aug-11-23 08:00AM	Ensysce Biosciences Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-08-23 08:15AM	Ensysce Biosciences Announces IRB Approval of Key Study Protocol (ACCESSWIRE)
07:05AM	ENSC Gets Important Study Approval (Zacks Small Cap Research)
Jul-26-23 08:05AM	Ensysce Biosciences Announces Engagement of Alacrita Consulting (ACCESSWIRE)
Jun-27-23 08:05AM	Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo (ACCESSWIRE)
Jun-15-23 01:34PM	Revolutionizing Pain Relief: The next generation of opioids \| Interview with Ensysce Biosciences CEO (News Direct)
Jun-13-23 04:15PM	Ensysce Biosciences Regains Compliance with Nasdaq (ACCESSWIRE)
Jun-07-23 09:55AM	Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website (ACCESSWIRE)
Jun-06-23 08:05AM	Ensysce Biosciences to Participate in Upcoming Industry Events (ACCESSWIRE)
May-16-23 07:25AM	ENSC: ENSC Provides an Attractive Entry Point (Zacks Small Cap Research)
May-15-23 04:30PM	Ensysce Biosciences Reports First Quarter 2023 Financial Results (ACCESSWIRE)
May-12-23 04:40PM	Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering (ACCESSWIRE)
May-10-23 08:00AM	Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering (ACCESSWIRE) -14.11%
May-09-23 01:31PM	Why Are Ensysce Biosciences Shares Are Trading Higher Today (Benzinga) +19.48%
08:00AM	Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection (ACCESSWIRE)
07:45AM	ENSC: ENSC Announces Potential Game-Changing Results (Zacks Small Cap Research)
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey) -10.49%
Apr-19-23 09:25AM	Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development (ACCESSWIRE) +8.60%
Apr-11-23 08:10AM	Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website (ACCESSWIRE)
Apr-03-23 08:06AM	ENSC: Ensysce Provides Positive Result on Non-Addictive Opioid (Zacks Small Cap Research)
08:00AM	Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614 (ACCESSWIRE)
Mar-30-23 05:37PM	Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results (ACCESSWIRE) -28.43%
Mar-22-23 08:05AM	Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study (ACCESSWIRE) -8.70%
07:32AM	ENSC: Tackling the Opioid Crisis (Zacks Small Cap Research)
Mar-09-23 03:42PM	10 Penny Stocks with Insider Buying (Insider Monkey)
Mar-06-23 08:05AM	Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar (ACCESSWIRE) +9.63%
Feb-28-23 08:05AM	Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock (ACCESSWIRE)
Feb-23-23 08:05AM	Ensysce Biosciences Provides Corporate Update (ACCESSWIRE)
Feb-15-23 04:10PM	Ensysce Biosciences Receives Positive Nasdaq Listing Determination (ACCESSWIRE)
Feb-14-23 08:00AM	Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting (ACCESSWIRE)
Feb-07-23 08:05AM	Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules (ACCESSWIRE)
06:10AM	ENSC: Ensysce Continues to Progress Toward Opioid Solution (Zacks Small Cap Research)
Feb-03-23 08:00AM	Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering (ACCESSWIRE) -8.59%
Feb-01-23 08:05AM	Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock (ACCESSWIRE)
Jan-25-23 08:05AM	Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study (ACCESSWIRE) +18.56%
Jan-23-23 08:05AM	Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational (ACCESSWIRE)
08:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on January 25, 2023 (GlobeNewswire)
Jan-11-23 08:00AM	Ensysce Biosciences Issues 2023 Shareholder Letter (ACCESSWIRE)

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENSC

Ensysce Biosciences Inc

Upgrade your FINVIZ experience